Crescent Biopharma Inc.
CBIO | NASDAQ
$13.53
-$0.54 (-3.84%)
At close: Oct 30, 2026, 3:59 PM ET
$13.48
-$0.05 (-0.37%)
After-hours:
Oct 30, 2026, 4:18 PM ET
-3.84%
(1D)No price chart data available for 1D timeframe.
Rating
53.2
+3.0 ptsFundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #214/1028 (Top 21%)
Key Statistics
Market Data
Market Cap $502.56M
1D Range
13.34 14.39
52W Range
8.94 26.98
Valuation (TTM)
PE -1.78
PB 3.08
EV/EBITDA -2.04
Valuation (NTM)
Forward PE N/A
Forward PEG 0.03
Price Target $36.00
Cash Flow
FCF Yield -30.6%
SBC Adj. FCF Yield -33.5%
SBC Impact -9.6%
Margins
Gross Margin 100.0%
Operating Margin -1417.7%
FCF Margin -1292.8%
Growth (CAGR)
Revenue 3Y | 5Y 149.8% |
39.9%
Dil EPS 3Y | 5Y 58.4% |
34.6%
FCF 3Y | 5Y -77.4% |
-29.6%
Returns
ROA -89.2%
ROE -97.8%
ROIC -102.3%
Financial Health
Net Cash
$171.59M
Current Ratio 9.66
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific an...
Sector Healthcare
Industry Biotechnology
Employees 44
IPO Date Jan 10, 2014
Website crescentbiopharma.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$36.00
Upside
+166.08%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CBIO